New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
10:12 EDTGWPHGW Pharma rises after analyst sees promise in marijuana-derived epilepsy drug
Shares of GW Pharmaceuticals (GWPH) are climbing after research firm Piper Jaffray sharply raised its price target on the stock after attending a conference of the Dravet Foundation and speaking with epilepsy specialists. Dravet Syndrome is a form of epilepsy and the foundation raises money to combat it. GW has created a drug for the treatment of seizures based on cannabinoid, one of the components of marijuana. WHAT'S NEW: After attending the conference, Piper Jaffray analyst Dr. Joshua Schimmer wrote that he is more confident that GW's epilepsy treatment, Epidiolex, is "a highly attractive emerging therapy" for the disease. Epidiolex has a unique combination of safety and effectiveness, the analyst believes. Children with Dravet who are treated with Epidiolex have fewer seizures and can take lower doses of other medicines, while the social skills of many of them improve, Schimmer reported. He increased his price target on GW to $147 from $97 and kept an Overweight rating on the stock. WHAT'S NOTABLE: Eventually Epidiolex's use should extend far beyond difficult to treat cases of Dravet, the analyst forecast. A logical potential use for the drug is as a treatment for autism, Schimmer believes. There is a strong correlation between autism and Dravet Syndrome or frequent seizures, he explained. Additionally, there are "anecdotal reports" that autism patients have responded very well to cannabinoids and GW and specialists are becoming more confident that a number of autism patients will benefit from them, he reported. PRICE ACTION: In early trading, GW Pharmaceuticals shares climbed $7.30, or 7.6%, to $103.44.
News For GWPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
07:47 EDTGWPHPiper Jaffray to hold a conference
Subscribe for More Information
November 30, 2015
07:58 EDTGWPHGW Pharmaceuticals re-initiated with a Buy at Roth Capital
Subscribe for More Information
November 20, 2015
06:01 EDTGWPHGW Pharmaceuticals selloff yesterday an overreaction, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says shares of GW Pharmaceuticals sold off yesterday in response to an abstract posted for the American Epilepsy Society conference in December describing a single center's experience with Epidiolex for seizures. The results support the drug's potent activity in Dravet syndrome, but some investors have concern with the drop-out rate due to inactivity and the lower response rate compared to what has otherwise been described for Epidiolex, Schimmer told investors last night in a research note titled "Over-Reacting To A Tree When The Forest Remains In Good Shape." The dropout rate is likely a result of the center's "highly questionable" practice of stopping drug if seizure reduction doesn't reach 50%, while the lower response rate at one site shouldn't detract from a "much bigger, robust clinical experience spanning multiple centers," Schimmer argues. He reiterates an Overweight rating on GW with a $147 price target. The stock closed yesterday down $5.42 to $82.30.
November 19, 2015
15:33 EDTGWPHGW Pharmaceuticals drops 10% after epilepsy study abstract posted
The conclusion of the abstract, posted to the the site of the American Epilepsy Society, stated: "Add-on pure CBD was associated with more than 50% seizure reduction in one-third of patients at 3 months...Best results were obtained in patients with Dravet syndrome, although one experienced a severe increase in seizure frequency."
15:31 EDTGWPHAbstract for GW Pharmaceuticals epilepsys study posted to AES site
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use